Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study".

Xu Q

Open source

DOI
10.3802/jgo.2025.36.e140
Published
2025 Nov
Container
Journal of gynecologic oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3802/jgo.2025.36.e140,
  title = {Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study".},
  author = {Xu Q},
  year = {2025},
  journal = {Journal of gynecologic oncology},
  doi = {10.3802/jgo.2025.36.e140},
  url = {https://doi.org/10.3802/jgo.2025.36.e140}
}

RIS

TY  - JOUR
TI  - Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study".
AU  - Xu Q
PY  - 2025
JO  - Journal of gynecologic oncology
DO  - 10.3802/jgo.2025.36.e140
UR  - https://doi.org/10.3802/jgo.2025.36.e140
ER  - 

APA

Q, X. (2025). Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study".. Journal of gynecologic oncology. https://doi.org/10.3802/jgo.2025.36.e140

Source records